FDA and OS Therapies hold Type C meeting regarding phase IIb clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma

FDA debuts precheck manufacturing program to boost domestic drug development

FDA has launched a venture in onshoring domestic drug development called the Precheck Pilot Program.

February 06, 2026

FDA issues a boxed warning for capecitabine and fluorouracil on risks associated with DPD deficiency

FDA announced recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase deficiency.

February 06, 2026

Vol.52 No.05

Podcast

The soul of oncology: Centering patient stories amid funding saga

Last week’s issue of The Cancer Letter included an obituary that the entire staff at The Cancer Letter had been dreading for years: Abdallah Abou Zahr, an oncologist at Roger Maris Cancer Center in Fargo, ND, died Jan. 23 of a liposarcoma after a five-year battle with the disease.

February 04, 2026

Obituary

Abdallah Abou Zahr, an oncologist whose cancer story resonated widely, dies of liposarcoma at 42

On Jan. 24, Shauna Erickson-Abou Zahr posted these words on her Instagram feed.

January 30, 2026

Vol.52 No.04

Cancer Policy

FDA delays drug reviews in new voucher program amid safety, efficacy concerns

The reviews of two drugs granted priority review via FDA’s new priority voucher program, Commissioner’s National Priority Voucher (CNPV) Pilot Program, have been delayed.

January 30, 2026

Vol.52 No.04

By Claire Marie Porter

Drugs & Targets

FDA approves Darzalex Faspro as quad regimen for all newly diagnosed MM

FDA has approved Darzalez Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplant eligibility.

January 30, 2026

Vol.52 No.04

FDA and OS Therapies hold Type C meeting regarding phase IIb clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma

YOU MAY BE INTERESTED IN

FDA debuts precheck manufacturing program to boost domestic drug development

FDA issues a boxed warning for capecitabine and fluorouracil on risks associated with DPD deficiency

The soul of oncology: Centering patient stories amid funding saga

Abdallah Abou Zahr, an oncologist whose cancer story resonated widely, dies of liposarcoma at 42

FDA delays drug reviews in new voucher program amid safety, efficacy concerns

FDA approves Darzalex Faspro as quad regimen for all newly diagnosed MM

Renew today!

Subscriber content

Never miss an issue!

Login